Group 1 - The company held its 20th temporary board meeting on July 28, 2025, where it approved the acquisition of 25% equity in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. [1][12] - The acquisition was approved with 7 votes in favor, 0 against, and 0 abstentions, and the related directors recused themselves from the vote [2][5][12] - The transaction is classified as a related party transaction due to the controlling relationship between the parties involved [8][14] Group 2 - The total assessed value of 100% equity in Shanghai Zhongyuan Jisheng is RMB 15.2783 million, with the agreed transfer price for the 25% stake set at RMB 3,819,575 [9][10][20] - The transaction does not constitute a major asset restructuring and does not require shareholder approval [9][13] - The company aims to enhance operational efficiency and increase resource investment in adult health cell storage business through this acquisition [30][31] Group 3 - The company plans to establish its East China headquarters in Shanghai and has signed a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd. [34][36] - The total rent for the leased property is RMB 12,239,910, with a rental period from August 1, 2025, to July 31, 2028 [35][36] - The rental price is set at RMB 6 per day per square meter, with options for payment that include discounts for upfront payments [36][49] Group 4 - The lease agreement includes provisions for shared use of certain areas and specifies that the company will not incur additional business dependencies on related parties [56][57] - The company’s independent directors have reviewed and approved the lease agreement, confirming that it aligns with the company's strategic planning and does not harm shareholder interests [57][58]

证券代码：600645 证券简称：中源协和 公告编号：2025-029 中源协和细胞基因工程股份有限公司 十一届二十次临时董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二十次 临时董事会会议于 2025 年 7 月 28 日以通讯表决方式召开。会议通知和会议资 料已于 2025 年 7 月 23 日以电子邮件形式向全体董事发出。应出席会议的董事 定，表决有效。经出席会议的董事认真审议，通过了以下决议： 中源济生细胞科技有限公司股东所持部分股权暨关联交易的议案》； 本议案经公司第十一届董事会独立董事专门会议 2025 年第二次会议审议通 过。 具体详见同日公告《公司关于收购子公司上海中源济生细胞科技有限公司 股东所持部分股权暨关联交易的公告》。 关联董事龚虹嘉先生、吴珊女士回避表决。 生物技术有限公司签署房地产租赁合同暨关联交易的议案》。 本议案经公司第十一届董事会独立董事专门会议 2025 年第二次会议审议通 过。 具体详见同日公告《公司关于与上海 ...

Core Viewpoint - The company plans to temporarily use idle raised funds to supplement working capital, which has been approved by the board and supervisory committee, ensuring compliance with relevant regulations [4][5]. Group 1: Fundraising Overview - The company raised a total of 446,999,922.07 RMB through a non-public offering of 27,815,801 shares at a price of 16.07 RMB per share, with a net amount of 444,449,922.07 RMB after deducting related issuance costs [1]. - As of May 15, 2025, the company has a remaining balance of 33,792.44 million RMB in raised funds, with 120 million RMB of idle funds allocated for cash management [2]. Group 2: Temporary Use of Idle Funds - The company intends to use up to 180 million RMB of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months from the board's approval [2]. - The company assures that the use of these funds will not affect the normal progress of the fundraising investment plan and will be related to its main business operations [2]. Group 3: Approval Procedures and Opinions - The proposal to use idle raised funds has been approved by the company's board and supervisory committee in their respective meetings [3]. - The independent financial advisor has confirmed that the proposal complies with relevant regulations and is in the best interest of the company and its shareholders, with no indication of changing the purpose of the raised funds [4][5].

证券代码：600645 证券简称：中源协和 公告编号：2025-022 十一届九次临时监事会会议决议公告 中源协和细胞基因工程股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届九次临 时监事会会议于 2025 年 5 月 20 日以通讯表决方式召开。会议通知和会议资料 已于 2025 年 5 月 17 日以电子邮件形式向全体监事发出。应出席会议的监事 3 名，实际出席会议的监事 3 名。会议符合《公司法》和《公司章程》的规定， 表决有效。经出席会议的监事认真审议，通过了以下决议： 金暂时补充流动资金的议案》。 结合公司生产经营需求，为提高募集资金使用效率，降低公司财务费用， 在不影响募集资金投资计划正常进行的前提下，公司拟使用不超过1.8亿元的闲 置募集资金暂时补充流动资金，使用期限自公司董事会会议审议通过之日起不 超过12个月。 监事会认为：本次公司使用闲置募集资金暂时补充流动资金，相关程序符 合中国证券监督管理委员会《上市公司监管指引第 2 号——上市公 ...

Group 1 - The company will hold its 2024 Annual General Meeting on May 20, 2025, combining on-site and online voting methods [2][6] - The meeting will take place at the company's conference room located at No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin [2][10] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the same day, with specific time slots for trading and internet voting [3][4] Group 2 - The agenda includes listening to the independent directors' 2024 annual work report, with no special resolutions or related party voting issues [6][22] - Shareholders must complete voting for all proposals before submission, and multiple accounts can be used for voting, but only the first vote will be counted [8][9][7] - The company will provide a proxy voting option for shareholders unable to attend, with specific documentation required for both individual and corporate shareholders [12][14][20] Group 3 - The company will also hold a 2024 Annual Performance Presentation on May 22, 2025, from 15:00 to 16:30, via the China Securities Journal's website [21][22] - Investors can submit questions via email before the presentation, and the company will address common concerns during the event [21][24] - Key personnel attending the performance presentation include the Vice Chairman, General Manager, and Independent Director [24][25]